MA-0204

2095128-17-7

C25H27F3N2O4

DMSO : 43.33 mg/mL (90.94 mM; Need ultrasonic)

Cell Cycle/DNA Damage

MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor delta (PPARdelta) modulator with EC₅₀s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARdelta, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD)^[1]. IC50 & Target: EC50: 0.4 nM (human PPARdelta), 7.9 nM (mouse PPARdelta) and 10 nM (rat PPARdelta)^[1] In Vitro: MA-0204 is >10, 000-fold selective for activation of PPARdelta over PPARalpha and PPARgamma receptors. MA-0204 exhibits high protein binding to mouse plasma, good permeability and low potential for efflux. C^[1].

MA-0204 (1.2-12 nM) improves fatty acid oxidation in DMD patient muscle myoblasts mice^[1].

MA-0204 (0.04-40 nM) engages target gene expression in DMD patient muscle myoblasts^[1].

In Vivo: PPARdelta (30, 100 mg/kg) increases target gene transcription in the muscle^[1].